微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 77.82% | -7.85% | -5.6% | 20/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 82.43% | -3.91% | 0.68% | 15/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 81.87% | -5.15% | -3.81% | 18/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 85.11% | 1.53% | 0.79% | 15/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 84.44% | 0.49% | -1.56% | 15/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 85.78% | -0.16% | -0.61% | 13/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 86.31% | 1.68% | 2.96% | 6/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 83.83% | -2.98% | -0.24% | 15/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 84.04% | -2.3% | -2.19% | 12/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 85.92% | -0.33% | 1.22% | 11/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 84.89% | -1.13% | -1.76% | 10/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 86.41% | 9.98% | 0.46% | 10/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 86.02% | 7.55% | -0.22% | 10/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 86.21% | 7.69% | 0.41% | 9/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 85.86% | 7.61% | 9.28% | 13/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 78.57% | 14.04% | -1.76% | 24/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 79.98% | 15.77% | -0.1% | 21/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 80.06% | 13.28% | 0.33% | 24/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 79.79% | 12.98% | 15.81% | 23/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 68.9% | 13.23% | -0.28% | 47/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 69.09% | 4.3% | -2.25% | 36/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 70.67% | 4.79% | 0.07% | 36/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 70.63% | 2.3% | 16.07% | 30/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 60.85% | 2.87% | -8.14% | 58/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 66.24% | 7.95% | -1.79% | 37/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 67.45% | 8.78% | -2.3% | 36/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 69.04% | 20.51% | 16.71% | 27/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 59.15% | -1.94% | -3.6% | 62/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 61.36% | -6.26% | -1.03% | 42/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 62% | -10.62% | 8.22% | 44/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 57.29% | -21.9% | -5.02% | 45/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 60.32% | -10.86% | -7.85% | 51/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 65.46% | -5.18% | -5.64% | 27/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 69.36% | 1.22% | -5.44% | 22/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 73.35% | 5.22% | 8.41% | 15/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 67.66% | 11.93% | -1.98% | 29/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 69.03% | 11.7% | 0.73% | 18/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 68.53% | 9.11% | -1.7% | 18/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 69.71% | 6% | 15.32% | 16/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 60.45% | -2.96% | -2.18% | 31/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 61.8% | -2.66% | -1.61% | 21/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 62.81% | -3.63% | -4.49% | 23/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 65.77% | -2.63% | 5.57% | 13/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |